Faes Farma’s Q4 18 sales number outperformed our as well as the street’s expectations. Revenue was up by 7.7% to €88.1m, mainly driven by the strong performance of Bilastine’s licensing and milestone revenue (>+100%), Hidroferol (>+20%) and Ristaben (+14%). On the profitability front, the EBITDA margin was up by 178bp to 20.4%, mainly on the back of lower COGS (33.5% of sales vs 35.2% in Q4 17), unlike in Q3, which was driven from the sales and marketing front. Th
05 Mar 2019
Solid performance in Q4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid performance in Q4
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
05 Mar 2019 -
Author:
Kamla Singh -
Pages:
3
Faes Farma’s Q4 18 sales number outperformed our as well as the street’s expectations. Revenue was up by 7.7% to €88.1m, mainly driven by the strong performance of Bilastine’s licensing and milestone revenue (>+100%), Hidroferol (>+20%) and Ristaben (+14%). On the profitability front, the EBITDA margin was up by 178bp to 20.4%, mainly on the back of lower COGS (33.5% of sales vs 35.2% in Q4 17), unlike in Q3, which was driven from the sales and marketing front. Th